In the CMML group, recurrently altered pathways included epigenetic regulators (e.g., DNMT3A) and FLT3 TKD/RAS kinase mutations, with all five cases showing these mutations. This evidence concerns the gene DNMT3A and chronic myelomonocytic leukemia.